You are here
Press Releases from AlphaMed Press
DURHAM, N.C., June 23, 2015 /PRNewswire-iReach/ -- To date, the only definitive treatment for heart failure – an organ transplant – is hampered by both the limited number of organ donors and the potential for the patient's body to reject the new heart. However, findings of a study published in STEM CELLS Translational Medicine demonstrate the promise in regenerating cardiac tissue using engineered patches made up of a mixture of fibrin and mesenchymal stem cells (MSCs) derived from human umbilical cord blood.
DURHAM, N.C., May 29, 2015 /PRNewswire-iReach/ -- A study released today in STEM CELLS Translational Medicine could open the door to a new therapy to potentially expand the current window of time for treating patients after they have experienced a stroke (five times beyond that of a clot-busting drug) and significantly improves their chance of recovery.
DURHAM, N.C., May. 27, 2015 /PRNewswire-iReach/ -- A new study appearing today in STEM CELLS Translational Medicine, designed to test how stem cell injections affect primates with spinal cord injury (SCI), showed the treatments significantly improved the animals' motor function recovery and promoted faster healing, too. The researchers call their findings a step forward toward the goal of improving outcomes for humans with chronic SCI.
DURHAM, N.C., May. 1, 2015 /PRNewswire-iReach/ -- Stem cells are a safe therapy for patients with amyotrophic lateral sclerosis (ALS), according to the results of a recently completed phase 1 clinical trial. Details of the trial, conducted by scientists in South Korea, are published in this month's issue of STEM CELLS Translational Medicine.
DURHAM, NC (PRWEB) March 31, 2015 /PRWeb/ -- Stem cells may provide Crohn’s disease sufferers relief from a common, potentially dangerous side effect – fistulas – according to the results of a phase 2 clinical trial published in the latest issue of STEM CELLS Translational Medicine (SCTM). After receiving an injection of their own adipose-derived stem cells (ASC), which are collected from fat tissue, the fistulas in 75 percent of the trial participants were completely healed within eight weeks of their last treatment and remained so two years later.
DURHAM, NC (PRWEB) March 19, 2015 /PRWeb/ -- A new study appearing in STEM CELLS Translational Medicine has moved science one step closer to finding a simple treatment for erectile dysfunction (ED) after prostate cancer surgery, eschewing the usual pharmaceutical drug route with potential for harmful side effects, in favor of stem cell therapy that can help the body regenerate.
The study, conducted in rats, compares the effectiveness of using a byproduct of liposuction — uncultured stromal vascular fraction (SVF) — with adipose-derived stem cells (ADSCs) cultured in the lab to treat ED caused by injury to the cavernous nerve (CN). This nerve, which facilities erection, is sometimes injured during a radical prostatectomy to treat prostate cancer.
Scientists report in the current issue of STEM CELLS Translational Medicine that they have been able to clone a line of defective stem cells behind a rare, but devastating disease called Fanconi Anemia (FA). Their achievement opens the door to drug screening and the potential for a new, safe treatment for this often fatal disease.
FA is a hereditary blood disorder that leads to bone marrow failure (FA-BMF) and cancer. Patients who suffer from FA have a life expectancy of 33 years. Currently, a bone marrow transplant offers the only possibility for a cure. However, this treatment has many risks associated with it, especially for FA patients due to their extreme sensitivity to radiation and chemotherapy.